Table 2 Characteristics of T1b patients with or without chemotherapy in the whole cohort and matched cohorts
Characteristic | T1b: whole cohort [cases (%)] | T1b: Matched cohort [cases (%)] | ||||
|---|---|---|---|---|---|---|
Chemotherapy | P-value | Chemotherapy | P-value | |||
No | Yes | No | Yes | |||
GRADE | < 0.01 | 0.83 | ||||
I | 9790 (45.96%) | 466 (12.77%) | 443 (16.07%) | 455 (16.50%) | ||
II | 9455 (44.38%) | 1442 (39.53%) | 1197 (43.42%) | 1176 (42.66%) | ||
III | 2058 (9.66%) | 1740 (47.70%) | 1117 (40.52%) | 1126 (40.84%) | ||
SURGERY | < 0.01 | 0.92 | ||||
Breast-conserving | 15,453 (72.54%) | 2235 (61.27%) | 1676 (60.79%) | 1665 (60.39%) | ||
Total mastectomy | 4615 (21.66%) | 1147 (31.44%) | 869 (31.52%) | 883 (32.03%) | ||
Modified radical mastectomy | 1235 (5.80%) | 266 (7.29%) | 212 (7.69%) | 209 (7.58%) | ||
RADIATION | < 0.01 | 0.77 | ||||
No | 7997 (37.54%) | 1569 (43.01%) | 1238 (44.90%) | 1227 (44.50%) | ||
Yes | 13,306 (62.46%) | 2079 (56.99%) | 1519 (55.10%) | 1530 (55.50%) | ||
SUBTYPE | < 0.01 | 0.96 | ||||
HoR + /HER2- | 19,702 (92.48%) | 1509 (41.37%) | 1512 (54.84%) | 1508 (54.70%) | ||
HoR + /HER2 + | 712 (3.34%) | 876 (24.01%) | 538 (19.51%) | 548 (19.88%) | ||
HoR-/HER2 + | 147 (0.69%) | 339 (9.29%) | 139 (5.04%) | 144 (5.22%) | ||
HoR-/HER2- | 742 (3.48%) | 924 (25.33%) | 568 (20.60%) | 557 (20.20%) | ||
AGE (year) | < 0.01 | 0.83 | ||||
< 60 | 7510 (35.25%) | 2243 (61.49%) | 1416 (51.36%) | 1424 (51.65%) | ||
≥ 60 | 13,793 (64.75%) | 1405 (38.51%) | 1341 (48.64%) | 1333 (48.35%) | ||